Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 286368, 10 pages
Research Article

FOXP3+ T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF Agents

1Department of Internal Medicine, Inflammatory Bowel Disease Unit, Complesso Integrato Columbus, Catholic University, Largo Gemelli 8, 00168 Rome, Italy
2Department of Gynaecology, Catholic University, Rome, Italy
3Inflammatory Bowel Disease Unit, IRCCS Clinical Institute Humanitas, Rozzano, Milano, Italy
4Department of Paediatric Haematology/Oncology, IRCCS Bambin Gesù Children’s Hospital, Rome, Italy

Received 30 April 2013; Accepted 8 July 2013

Academic Editor: Silvia Gregori

Copyright © 2013 Luisa Guidi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

In the table 1S, peripheral blood (PB) CD4+CD25+FOXP3+ levels in all groups of patients (IBD and controls) before and after anti-TNFα therapy are showed.

In the figure 1S, Treg frequencies in peripheral blood (PB) of IBD clinical responders (n= 26) before and after anti-TNFα therapy are showed (p value by t test for paired samples).

  1. Supplementary Material